Exenatide
- Generic Name
- Exenatide
- Brand Names
- Bydureon, Byetta
- Drug Type
- Biotech
- CAS Number
- 141758-74-9
- Unique Ingredient Identifier
- 9P1872D4OL
- Background
Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulations. Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021. Bydureon BCise, an auto-injector extended-release formulation, remains available.
- Indication
Exenatide is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. An extended-release formulation is available which is indicated in patients ≥10 years old, while the immediate-acting formulation is approved only for adult patients.
- Associated Conditions
- Type 2 Diabetes Mellitus
Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin
- First Posted Date
- 2002-06-10
- Last Posted Date
- 2015-02-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 336
- Registration Number
- NCT00039013
- Locations
- 🇺🇸
Thomas Jefferson University Diabetes Research Center, Philadelphia, Pennsylvania, United States
🇺🇸Philadelphia Health Associates, Philadelphia, Pennsylvania, United States
🇺🇸St. Agnes Health Care, Baltimore, Maryland, United States
Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea
- Conditions
- Diabetes Mellitus, Non-Insulin-Dependent
- Interventions
- Drug: Placebo
- First Posted Date
- 2002-06-10
- Last Posted Date
- 2015-02-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 377
- Registration Number
- NCT00039026
- Locations
- 🇺🇸
ANA Ventures, LLC, Mesa, Arizona, United States
🇺🇸Comprehensive Diabetes-Endocrine Medical Associates, Redwood City, California, United States
🇺🇸St. Agnes Health Care, Baltimore, Maryland, United States
Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Non-Insulin-Dependent
- Interventions
- Drug: Placebo
- First Posted Date
- 2002-05-08
- Last Posted Date
- 2015-02-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 734
- Registration Number
- NCT00035984
- Locations
- 🇺🇸
Diabetes and Endocrinology Specialists, Chesterfield, Missouri, United States
🇺🇸Holston Medical Group, Kingsport, Tennessee, United States
🇺🇸University of Mississippi Medical Center, Jackson, Mississippi, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.